August 12, 2013
Mylan Inc. on Monday dodged a $15 million breach of contract suit from Bristol-Myers Squibb Co. after a New York federal judge found that an agreement between the companies didn't bar Mylan's sales of an HIV drug in Venezuela, although a patent infringement complaint is still possible.